Akt inhibitors in clinical development for the treatment of cancer

Bibliography

• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Clark JI, Atkins MB, Urba WJ, Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:3133-40
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines: renal cell carcinoma. Available from: http://www.nccn.org; [Last accessed 29 March 2010]
   Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71
   PubMed Web of Science ®Google Scholar
• Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991;201:4754-81
   Google Scholar
• Jones PF, Jakubowicz T, Pitossi FJ, Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA 1991;88:4171-5
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254:274-7
   PubMed Web of Science ®Google Scholar
• Jones PF, Jakubowicz T, Hemmings BA. Molecular cloning of a second form of rac protein kinase. Cell Regul 1991;2:1001-9
   PubMedGoogle Scholar
• Cheng JQ, Godwin AK, Bellacosa A, AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71
   PubMed Web of Science ®Google Scholar
• Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999;274:9133-6
   PubMed Web of Science ®Google Scholar
• James SR, Downes CP, Gigg R, Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J 1996;31:709-13
   Google Scholar
• Frech M, Andjelkovic M, Ingley E, High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 1997;272:8474-81
   PubMed Web of Science ®Google Scholar
• Mure H, Matsuzaki K, Kitazato KT, Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol 2010;12:221-32
   PubMed Web of Science ®Google Scholar
• Al-Saad S, Donnem T, Al-Shibli K, Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009;29:4175-83
   PubMed Web of Science ®Google Scholar
• Boormans JL, Hermans KG, van Leenders GJ, An activating mutation in AKT1 in human prostate cancer. Int J Cancer 2008;123:2725-6
   PubMed Web of Science ®Google Scholar
• Zhang HH, Huang J, Duvel K, Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 2009;4(7):e6189
   PubMedGoogle Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62
   PubMed Web of Science ®Google Scholar
• Ruiter GA, Zerp SF, Bartelink H, Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti Cancer Drugs 2003;14(2):167-73
   PubMed Web of Science ®Google Scholar
• Li Z, Tan F, Tong J, Perifosine, as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical models. AACR Meeting Abstracts; 2009. p. 3205
   Google Scholar
• Vink SR, Schellens JHM, Beijnen JH, Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006;80:207-13
   PubMed Web of Science ®Google Scholar
• Hilgard P, Klenner T, Stekar J, D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997;33:442-6
   PubMed Web of Science ®Google Scholar
• Van Ummersen L, Binger K, Volkman J, A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004;10:7450-6
   PubMed Web of Science ®Google Scholar
• Verheij M, Vink SR, Schellens JHM, Phase I study of combined treatment with the oral alkyl-lysophospholipid (ALP) perifosine and radiation in patients with advanced solid tumors. Meeting Abstracts. J Clin Oncol 2004;22(14 Suppl):3064
   Google Scholar
• NCT00398814: Phase I study of perifosine + sorafenib for patients with advanced cancers. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00398814 [Last accessed 1 September 2010]
   Google Scholar
• NCT01049841: perifosine with temsirolimus for recurrent pediatric solid tumors. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01049841 [Last accessed 1 September 2010]
   Google Scholar
• Breuleux M, Klopfenstein M, Stephan C, Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009;8:742-53
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Leleu X, Rubin N, Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). Meeting Abstracts. J Clin Oncol 2008;26(15 Suppl):8546
   Google Scholar
• Richardson P, Lonial S, Jakubowiak A, Multi-center Phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood (ASH Annual Meeting Abstracts) 2007;110:1164
   Web of Science ®Google Scholar
• Richardson P, Wolf JL, Jakubowiak A, Perifosine in combination with bortezomib and dexamethasone extends progression-free survival and overall survival in relapsed/refractory multiple myeloma patients previously treated with bortezombib: updated Phase I/II trial results. Blood (ASH Annual Meeting Abstracts) 2009;114:1869
   Google Scholar
• NCT01002248: assessment of efficacy and safety of perifosine, bortezomib and dexamethasone in multiple myeloma patients. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT01002248 [Last accessed 1 September 2010]
   Google Scholar
• NCT00391560: Phase II study of perifosine in patients with refractory and relapsed leukemia. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00391560 [Last accessed 1 September 2010]
   Google Scholar
• Vogelzang NJ, Hutson TE, Samlowski W, Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. Meeting Abstracts. J Clin Oncol 2009;27(15S):5034
   Google Scholar
• Cho DC, Figlin RA, Flaherty KT, A Phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). Meeting Abstracts. J Clin Oncol 2009;27(15S):5101
   Google Scholar
• Chee KG, Longmate J, Quinn DI, The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a Phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5:433-7
   PubMed Web of Science ®Google Scholar
• AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non Small Cell Lung Cancer. Quebec, Canada: AEterna Zentaris Press Release, June 8, 2009: Available from: http://www.aeternazentaris.com/en/ page.php?p=60&q=316 [Last accessed 1 September 2010]
   Google Scholar
• Vukelja S, Richards D, Campos LT, Randomized Phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer. Meeting Abstracts. J Clin Oncol 2009;27(15S):4081
   Google Scholar
• NCT01097018: a Phase III randomized study to assess the efficacy and safety of perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01097018?term=NCT01097018&rank=1 [Last accessed 1 September 2010]
   Google Scholar
• Chee KG, Lara PN, Longmate J, The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): a Phase II California cancer consortium trial. Meeting Abstracts. J Clin Oncol 2005;23(16 Suppl):4642
   Google Scholar
• Marsh RdeW, Rocha Lima CM, Levy DE, A Phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2007;30:26-31
   PubMed Web of Science ®Google Scholar
• Ernst D, Eisenhauer E, Wainman N, Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005;23:569-75
   PubMed Web of Science ®Google Scholar
• Argiris A, Cohen E, Karrison T, A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006;5:766-70
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, An allosteric Akt inhibitor, MK-2206 enhanced anti-tumor efficacy by standard of care agents or molecular targeted drugs in vitro and in vivo. AACR Meeting Abstracts; 2009. p. 3707
   Google Scholar
• Lu W, Defeo-Jones D, Davis LJ, In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor. AACR Meeting Abstracts; 2009. p. 3714
   Google Scholar
• Trucksis M, Friedman E, Taylor A, A Phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers. AACR Meeting Abstracts; 2009. p. 3604
   Google Scholar
• Tolcher AW, Yap TA, Fearen I, A Phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). Meeting Abstracts. J Clin Oncol 2009;27(15S):3503
   PubMedGoogle Scholar
• Cappuzzo F, Magrini E, Ceresoli GL, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41
   PubMed Web of Science ®Google Scholar
• Yap TA, Patnaik A, Fearen I, First-in-class Phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):3009
   Google Scholar
• NCT00460278: study of XL418 in adults with solid tumors. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/ show/NCT00460278 [Last accessed 1 September 2010]
   Google Scholar
• Gallay N, Dos Santos C, Cuzin L, The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 2009;23:1029-38
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
   PubMed Web of Science ®Google Scholar
• Yoon H, Kim DJ, Ahn EH, Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 2009;108:832-8
   PubMed Web of Science ®Google Scholar
• US Patent Granted for Rexahn Pharmaceuticals Leading Cancer Candidate. Rockville, MD: Rexahn Pharmaceuticals Press Release, 6 November 2006. Available from: http://www.rexahn.com/cms/index. php/2006/11/us-patent-granted- for-rexahn-pharmaceuticals-leading- cancer-candidate-2/ [Last accessed 1 September 2010]
   Google Scholar
• Marshall J, Posey J, Hwang J, A Phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer. Meeting Abstracts. J Clin Oncol 2007;25(18 Suppl):3564
   Google Scholar
• NCT01028495: a safety and efficacy study of RX-0201 plus gemcitabine in metastatic pancreatic cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/ show/NCT01028495 [Last accessed 1 September 2010]
   Google Scholar
• Handrick R, Rubel A, Faltin H, Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 2006;80:199-206
   PubMed Web of Science ®Google Scholar
• Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents 2003;3:343-53
   PubMedGoogle Scholar
• Kugler W, Erdlenbruch B, Otten K, MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. Int J Oncol 2004;25:1721-7
   PubMed Web of Science ®Google Scholar
• NCT00460278: a phase 1 dose-escalation study of the safety and pharmacokinetics of XL418 administered orally daily to subjects with solid tumors. Available from: http://www.clinicaltrials.gov [Last accessed 7 September 2010]
   Google Scholar
• Bidyasar S, Kurzrock R, Falchook GS, A first-in-human Phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients. Meeting Abstracts. J Clin Oncol 2009;27(15S):3537
   Google Scholar
• Rhodes N, Knick V, McConnell R, GSK690693, a pan-AKT kinase inhibitor has potent anti-tumor activity and shows additive effect with lapatinib. 1 Annual Meeting. AACR Meeting Abstracts; 2007. p. 279
   Google Scholar
• Kumar R, Rhodes N, Knick V, GSK690693, a pan-AKT kinase inhibitor with potent pharmacodynamic and antitumor activity in vivo. 1 Annual Meeting. AACR Meeting Abstracts; 2007. p. 277
   Google Scholar
• Rhodes N, Heerding DA, Duckett DR, Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008;68:2366-74
   PubMed Web of Science ®Google Scholar
• Altomare DA, Zhang L, Deng J, GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res 2010;16:486-96
   PubMed Web of Science ®Google Scholar
• NCT00493818: open-label study to investigate the safety, tolerability, PK, and pharmacodynamics of the AKT inhibitor GSK690693. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/ show/NCT00493818 [Last accessed 1 September 2010]
   Google Scholar
• LoRusso P, Hurwitz H, Chiorean E, AKT inhibitor GSK690693: preliminary results from the first time in human study. 1 Annual Meeting. AACR Meeting Abstracts; 2008. p. LB-68
   Google Scholar
• Crouthamel M-C, Kahana JA, Korenchuk S, Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009;15:217-25
   PubMed Web of Science ®Google Scholar
• NCT00920257: a phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/ show/NCT00920257?term=NCT00920257&rank=1 [Last accessed 1 September 2010]
   Google Scholar
• Holland WS, Mack PC, Tepper CG, Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):e15041
   Google Scholar
• Barrios C, Liu M-C, Lee S, Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121-31
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS, Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dhakil S, Patel T, SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010: published online May 23 2010, doi: 10.1093/annonc/mdq260
   Google Scholar
• Cho DC, Cohen MB, Panka DJ, The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628-38
   PubMed Web of Science ®Google Scholar
• Brachmann SM, Hofmann I, Schnell C, Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009;106:22299-304
   PubMed Web of Science ®Google Scholar
• Burris H, Rodon J, Sharma S, First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):3005
   Google Scholar
• Iglehart JK. Prioritizing comparative-effectiveness research – IOM recommendations. N Engl J Med 2009;361:325-8
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554
   PubMed Web of Science ®Google Scholar
• Amzel LM, Huang C-H, Mandelker D, Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008;8:665-9
   PubMed Web of Science ®Google Scholar
• Sarker D, Reid AHM, Yap TA, de Bono JS. Targeting the PI3K/AKT Pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-805
   PubMed Web of Science ®Google Scholar
• Liu D, Hou P, Liu Z, Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-19
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92
   PubMed Web of Science ®Google Scholar
• Suzuki H, Freije D, Nusskern DR, Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9
   PubMed Web of Science ®Google Scholar
• Yoshimoto M, Cunha IW, Coudry RA, FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85
   PubMed Web of Science ®Google Scholar
• Mao JH, Kim IJ, Wu D, FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7
   PubMed Web of Science ®Google Scholar
• Pal SK, Figlin RA. Renal cell carcinoma in 2010: many options with little comparative data. Clin Adv Hematol Oncol 2010;8:1-7
   Google Scholar